# Milestone Scientific Inc.: Form 10-Q for the period ended Jun 30, 2019

- Company: [Milestone Scientific Inc.](/companies/mlss.md) (CIK 855683)
- Form: 10-Q
- Filed: 2019-08-14
- Accepted by EDGAR: Aug 14, 2019, 16:01 ET
- Period: 2019-06-30
- Accession: 0001437749-19-016799
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/855683/000143774919016799/mlss20190630_10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/855683/000143774919016799/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2019-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2019-04-01 to 2019-06-30 | $2.3m | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Revenue | 6 months, 2019-01-01 to 2019-06-30 | $4.2m | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Cost of revenue | 3 months, 2019-04-01 to 2019-06-30 | $752.2k | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months, 2019-01-01 to 2019-06-30 | $1.4m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2019-04-01 to 2019-06-30 | $1.5m | us-gaap:GrossProfit |
| Gross profit | 6 months, 2019-01-01 to 2019-06-30 | $2.8m | us-gaap:GrossProfit |
| Research and development | 3 months, 2019-04-01 to 2019-06-30 | $95.5k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months, 2019-01-01 to 2019-06-30 | $101.9k | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2019-04-01 to 2019-06-30 | $2.5m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months, 2019-01-01 to 2019-06-30 | $4.6m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2019-04-01 to 2019-06-30 | −$1.1m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2019-01-01 to 2019-06-30 | −$1.9m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2019-04-01 to 2019-06-30 | $14.2k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months, 2019-01-01 to 2019-06-30 | $18.6k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2019-04-01 to 2019-06-30 | −$1.0m | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2019-01-01 to 2019-06-30 | −$1.8m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2019-04-01 to 2019-06-30 | −$0.02 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months, 2019-01-01 to 2019-06-30 | −$0.04 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2019-04-01 to 2019-06-30 | −$0.02 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months, 2019-01-01 to 2019-06-30 | −$0.04 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2019-04-01 to 2019-06-30 | 45,366,237 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months, 2019-01-01 to 2019-06-30 | 41,904,581 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months, 2019-01-01 to 2019-06-30 | −$622.3k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months, 2019-01-01 to 2019-06-30 | $8.1k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2019-06-30 | $2.3m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2019-06-30 | $6.3m | us-gaap:AssetsCurrent |
| Total assets | at 2019-06-30 | $6.8m | us-gaap:Assets |
| Current liabilities | at 2019-06-30 | $6.0m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2019-06-30 | $6.0m | us-gaap:Liabilities |
| Shareholders' equity | at 2019-06-30 | $871.2k | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 23,522 characters.

The following discussions of the financial condition and results of operations should be read in conjunction with the financial statements and the notes to those statements included elsewhere in this annual report. Certain statements in this discussion and elsewhere in this report constitute forward-looking statements, within the meaning of section 21E of the Exchange Act, that involve risks and uncertainties. The actual results may differ materially from those anticipated in these forward-looking statements. See "Risk Factors" in Form 10-K at December 31, 2018.

### OVERVIEW

Our common stock was listed on the NYSE American on June 1, 2015 and trades under the symbol “MLSS”. We have developed a proprietary, computer-controlled anesthetic delivery instrument, using *The Wand*, a single use disposable handpiece. The instrument is marketed in dental sector under the trademark *CompuDent®*, and *STA Single Tooth Anesthesia System* and in medical sector under the trademark *CompuMed. CompuDent* is suitable for all dental procedures that require local anesthetic. *CompuMed* is suitable for many medical procedures regularly performed in plastic surgery, hair restoration surgery, podiatry, colorectal surgery, dermatology, orthopedics and several other disciplines. The dental instruments are sold in the United States, US territories, Canada, and in over 60 other countries abroad. In June 2017, the FDA approved our 510(k) application for marketing clearance in the United States of our *CompuFlo* Epidural Computer Controlled Anesthesia System. We are in the process of introductory meetings with medical device distributors within the United States and Europe. There have been five medical instruments sold in the United States to date and limited amounts sold internationally as of the reporting date. Certain of our medical instruments have obtained European CE mark approval and can be marketed and sold in most European countries.

In November 2018, Milestone Scientific received a letter from NYSE American LLC (the “Exchange”) stating that the Company was not in compliance with the continued listing standards as set forth in Section(s) 1003(a)(i), (ii), and (iii) of the NYSE American Company Guide (the “Company Guide”).On December 20, 2018, the Company submitted a plan of compliance (the “Plan”) to the Exchange addressing how it intends to regain compliance with Section(s) 1003(a)(i), (ii) and (iii) of the Company Guide by May 20, 2020.

On January 24, 2019, the Company received a letter from the Exchange stating that the Company’s Plan has been accepted by the Exchange. The Company is still not in compliance with Section(s) 1003(a)(i), (ii) and (iii) of the Company Guide and its listing on the Exchange is being continued pursuant to an extension granted by the Exchange. If the Company is not in compliance with the continued listing standards by May 20, 2020, or if the Company does not make progress consistent with the Plan, the Exchange will initiate delisting procedures as appropriate. The Company may appeal a staff delisting determination in accordance with Section 10 and Part 12 of the Company Guide.

In 2019, we remain focused on advancing efforts to achieve our three primary objectives in our medical sector, those being:

- Identify distributors in the United States for the Epidural instruments, now that FDA clearance has been received;
- Worldwide distribution of the *CompuFlo* Epidural Computer Controlled Anesthesia System; and
- Complete the Cosmetic device and obtain European Regulatory Approve (CE market clearance).

### Wand STA Dental Market

Since its market introduction in early 2007, the Wand/STA Instrument and prior C-CLAD products have been used to deliver over 66 million safe, effective and comfortable injections. The instrument has also been favorably evaluated in numerous peer-reviewed, published clinical studies and associated articles. Moreover, there appears to be a growing consensus among users that the STA Instrument is proving to be a valuable and beneficial instrument that is positively impacting the practice of dentistry worldwide.

Beginning January 1, 2016, Milestone Scientific entered into a non-exclusive distribution agreement with Henry Schein, Inc. (“Henry Schein”). In June 2016, that agreement was replaced with an exclusive distribution arrangement for our dental products for the United States and Canada with Henry Schein. Under this arrangement we have a semi-dedicated independent sales force visiting dentists.

To date, Henry Schein has endeavored to accomplish the goals set forth in the exclusive distribution agreement for *The Wand/* STA instrument and handpieces, including training of its exclusive products sale’s specialists. Specifically, up to 25 exclusive product sales specialists have now been fully trained as experts in the features, advantages and benefits of *The Wand/*STA instrument and handpieces and all are currently in the field selling the instrument.

Henry Schein also plans to increase the number of exclusive product specialist in 2019 and to train an additional customer service representative to support dentists across North America through its exclusive product sales customer call center, as business volume increases.

On the global front, we have granted exclusive marketing and distribution rights for the Wand/STA Instrument to select dental suppliers in various international regions in Asia, Africa, South America and Europe. They include FM Produkty Dla Stomatologii in Poland and Unident AB in the Scandinavian countries of Denmark, Sweden, Norway and Iceland.

### Medical Market

In September 2014, Milestone Medical received CE clearance to distribute their epidural and intra-articular instruments in the European Community (EU). Milestone Medical signed a distribution agreement in March 2015 with a medical distributor in Poland for the distribution of the epidural instrument. This distribution agreement was terminated in late 2016 due to the distributor’s inadequate performance under the distribution agreement. Milestone Medical is continuing to pursue distributors for the instrument in the EU community.

During 2016, Milestone Scientific filed for 510(k) marketing clearance with the U.S. Food and Drug Administration (FDA) for both intra-articular and epidural injections with the CompuFlo Epidural System. In June 2017, the FDA approved the CompuFlo Epidural System for epidural injections. Milestone Scientific is in the process of meeting with medical device distributors within the United States and foreign markets. Milestone Scientific’s immediate focus is on marketing its epidural device throughout the United States and Europe.

In December 2016, we received notification from the FDA that based upon the 510(k)-application submitted for intra- articular injections, we did not adequately document that the device met the equivalency standard required for 510(k) clearances. Following consultation with the FDA’s Office of Device Evaluation, we filed a new 510(k) application for the device in June 2018. In August 2018, the FDA provided Milestone Scientific with a list of questions on the intra-articular 510(k) application filed in June 2018. Due to the delay in responding to FDA questions Milestone Scientific will be required file a new 510(K) application, which we intend to do in 2019, subject to available funding.

In February and March 2018, Milestone Scientific hired an Executive VP of Global Sales and Marketing and a Vice President of US Sales to fill a significant gap in our commercialization efforts of the CompuFlo Epidural System. In October 2018, Milestone Medical signed a Distributor Agreement in the U.S. This agreement provides that this Distributor will purchase and hold an inventory of the CompuFlo Epidural System and disposables for sale. At this time there have been no minimum purchase established with the Distributor. This Distributor purchased five CompuFlo Epidural Systems and disposables after executing the Agreement.

In April 2019, Milestone Scientific entered an Agreement with American 3B Scientific, a leading supplier of didactic material for education, for the development and sale of a CompuFlo® Epidural Training Instrument. This instructional instrument utilizes the pressure sensing technology and will be utilized as a training instrument to improve epidural placement success. The first sale of this new medical instrument occurred in May 2019, for three instruments and three disposable kits.

We have entered into a limited number of distributor arrangements in Europe and the Middle East for our CompuFlo Epidural System. Our distribution strategy is initially aimed at having KOL's use and accept the device and initiates their own studies.

The following table shows a breakdown of Milestone Scientific’s product sales (net), domestically and internationally, by product category for the period ending June 30, 2019 and 2018:

| Domestic-US & Canada | Three months ended June 30, 2019 | 2018 | Six months ended June 30, 2019 | 2018 |
| --- | ---: | ---: | ---: | ---: |
| Devices | $146,289 | $11,505 | $270,285 | $132,553 |
| Handpieces | 1,030,391 | 1,158,975 | 1,819,544 | 1,927,506 |
| Other | 32,463 | 22,377 | 49,279 | 51,228 |
| **Total Domestic US & Canada** | $1,209,143 | $1,192,857 | $2,139,108 | $2,111,287 |
| **International ROW** |  |  |  |  |
| Devices | $339,570 | $367,450 | $624,915 | $652,518 |
| Handpieces | 631,129 | 839,194 | 1,262,839 | 1,418,021 |
| Other | 28,009 | 28,997 | 46,897 | 52,277 |
| **Total International-ROW** | $998,708 | $1,235,641 | $1,934,651 | $2,122,816 |
| **International-China** |  |  |  |  |
| Devices | $- | $- | $- | $- |
| Handpieces | 50,000 | - | 100,000 | - |
| Other | - | - | - | - |
| **Total International** | $50,000 | $- | $100,000 | $- |
| **Total Product Sales** | $2,257,851 | $2,428,498 | $4,173,759 | $4,234,103 |

23

### Results of Operations

The following table sets forth the consolidated results of operations for the three and six months ended June 30, 2019 compared to 2018. The trends suggested by this table may not be indicative of future operating results:

| Operating results: | For three months ended June 30, 2019 | 2018 | For six months ended June 30, 2019 | 2018 |
| --- | ---: | ---: | ---: | ---: |
| Product sales, net | $2,257,851 | $2,428,498 | $4,173,759 | $4,234,103 |
| Cost of products sold | 752,183 | 1,021,573 | 1,370,876 | 1,584,250 |
| Gross profit | 1,505,668 | 1,406,925 | 2,802,883 | 2,649,853 |
| Operating expenses: |  |  |  |  |
| Selling, general and administrative expenses | 2,517,970 | 2,821,837 | 4,627,023 | 5,840,601 |
| Research and development expenses | 95,529 | 9,775 | 101,875 | 235,592 |
| Loss from operations | (1,107,831) | (1,424,687) | (1,926,015) | (3,426,340) |
| Other income, and loss on earning net | 54,588 | 74,686 | 79,577 | 100,969 |
| Net loss | (1,053,243) | (1,350,001) | (1,846,438) | (3,325,371) |
| Net loss attributable to noncontrolling interests | 11,959 | 6,994 | 22,402 | 108,657 |
| Net loss attributable to Milestone Scientific Inc. | $(1,041,284) | $(1,343,007) | $(1,824,036) | $(3,216,714) |

| Cash flow: | June 30, 2019 | June 30, 2018 |
| --- | ---: | ---: |
| Net cash used in operating activities | $(622,279) | $(1,516,771) |
| Net cash used in investing activities | (8,104) | (4,531) |
| Net cash provided by financing activities | 2,224,547 | (250,000) |

### For the three months ended June 30, 2019 compared to three months ended June 30, 2018

### Net sales for 2019 and 2018 were as follows:

|  | 2019 | 2018 | Increase Decrease% |  |
| --- | ---: | ---: | ---: | ---: |
| Dental | $2,242,751 | $2,388,898 | $(146,147) | (6.12)% |
| Medical | 15,100 | 39,600 | (24,500) | (61.87)% |
| Total sales, net | $2,257,851 | $2,428,498 | $(170,647) | (7.03)% |

Consolidated revenue for the three months ended June 30, 2019 and 2018, were approximately $2.3 million and $2.4 million, respectively. The decrease of approximately $171,000 is primarily due to non-recurring order for handpieces and devices in 2018 from a Distributor in Mexico of approximately $400,000. We are in the process of attending medical device trade shows and attending introductory meetings with medical device distributors within the United States and European markets.

### Gross Profit for 2019 and 2018 were as follows:

|  | 2019 | 2018 | Increase Decrease% |  |
| --- | ---: | ---: | ---: | ---: |
| Dental | $1,499,329 | $1,613,059 | $(113,730) | (7.05)% |
| Medical | 6,339 | (206,134) | 212,473 | (103.08)% |
| Total gross profit | $1,505,668 | $1,406,925 | $98,743 | 7.02% |

Consolidated gross margin for the three months ended June 30, 2019 and 2018, was approximately 67% and 58%, respectively. The consolidated gross margin for the three months ended June 30, 2019 did not require inventory write downs or reserve of $290,000 as compared to the three months ended June 30,2018.

### Selling, general and administrative expenses for 2019 and 2018 were as follows:

|  | 2019 | 2018 | Increase Decrease% |  |
| --- | ---: | ---: | ---: | ---: |
| Dental | $870,548 | $957,464 | $(86,916) | (9.08)% |
| Medical | 574,772 | 630,254 | (55,482) | (8.80)% |
| Corporate | 1,072,650 | 1,234,119 | (161,469) | (13.08)% |
| Total selling, general and administrative expenses | $2,517,970 | $2,821,837 | $(303,867) | (10.77)% |

24

Consolidated selling, general and administrative expenses for the three months ended June 30, 2019 and 2018, were approximately $2.5 million and $2.8 million, respectively. The decrease of approximately $300,000 is categorized in several areas. Salaries, bonus, and recruiting fees decreased by approximately $434,000 due to the reduction of bonuses in 2019. Executive pension expense decreased by approximately $50,000 in the second quarter of 2019 as the Company’s funding commitment was finalized in 2018.Employee recruiting expense increased by approximately $70,000 as the Company is searching for specific commercial personnel. Patent amortization decreased by approximately $218,000 in 2019 compared to 2018 due to the impairment of the APAD patent in the third quarter of 2018. Intellectual regulatory quality control increased by approximately $92,000 as the Company prepares for changes in the European regulatory registration requirements Professional legal and accounting fees increased by approximately $143,000, related to a foreign operations, and additional consulting agreement with a third party. Additionally, marketing expense increased by approximately $53,000 to support dental and medical revenues.

### Research and Development for 2019 and 2018 were as follows:

|  | 2019 | 2018 | Increase Decrease% |  |
| --- | ---: | ---: | ---: | ---: |
| Dental | $- | $- | $- | 0.00% |
| Medical | 95,529 | 9,775 | 85,754 | 877.28% |
| Corporate | - | - | - | 0.00% |
| Total research and development | $95,529 | $9,775 | $85,754 | 877.28% |

Consolidated research and development expenses for the three months ended June 30, 2019 and 2018, were approximately $96,000 and $10,000, respectively. The increase is due to an instrument modification to certain Epidural instruments in the development of an Epidural training instrument. The Epidural training instrument is not approved for use on humans or in a clinical setting.

### Profit (Loss) from Operations for 2019 and 2018 were as follows:

|  | 2019 | 2018 | Increase Decrease% |  |
| --- | ---: | ---: | ---: | ---: |
| Dental | $629,474 | $723,084 | $(93,610) | (12.95)% |
| Medical | (664,658) | (846,164) | 181,506 | (21.45)% |
| Corporate | (1,072,647) | (1,301,607) | 228,960 | (17.59)% |
| Total loss from operations | $(1,107,831) | $(1,424,687) | $316,856 | (22.244)% |

The loss from operations was approximately $1 million and $1.4 million for the three months ending June 30, 2019 and 2018 respectively. The decrease in loss quarter over quarter is due to an increase of gross profit of approximately $100,000, a reduction in general administrative expense of approximately $300,00 and increase in research and development expense of approximately $100,000.

### For the six months ended June 30, 2019 compared to six months ended June 30, 2018

### Net sales for 2019 and 2018 were as follows:

|  | 2019 | 2018 | Increase Decrease% |  |
| --- | ---: | ---: | ---: | ---: |
| Dental | $4,158,259 | $4,158,003 | $256 | 0.01% |
| Medical | 15,500 | 76,100 | (60,600) | (79.63)% |
| Total sales, net | $4,173,759 | $4,234,103 | $(60,344) | (1.43)% |

Consolidated revenue for the six months ended June 30, 2019 and 2018 was approximately 4.2 million, respectively. The dental revenue for the six months ended June 30, 2018 included a non-recurring order for handpieces and devices in 2018 from a Distributor in Mexico of approximately $400,000. We are in the process of attending medical device trade shows and attending introductory meetings with medical device distributors within the United States and European markets.

### Gross Profit for 2019 and 2018 were as follows:

|  | 2019 | 2018 | Increase Decrease% |  |
| --- | ---: | ---: | ---: | ---: |
| Dental | $2,796,171 | $2,831,085 | $(34,914) | (1.23)% |
| Medical | 6,712 | (181,232) | 187,944 | (103.70)% |
| Total gross profit | $2,802,883 | $2,649,853 | $153,030 | 5.78% |

Consolidated gross margin for the six months ended June 30, 2019 and 2018, was approximately 67% and 63%, respectively

### Selling, general and administrative expenses for 2019 and 2018 were as follows:

|  | 2019 | 2018 | Increase Decrease% |  |
| --- | ---: | ---: | ---: | ---: |
| Dental | $1,674,731 | $1,818,325 | $(143,594) | (7.90)% |
| Medical | 1,061,178 | 1,308,306 | (247,128) | (18.89)% |
| Corporate | 1,891,114 | 2,713,970 | (822,856) | (30.32)% |
| Total selling, general and administrative expenses | $4,627,023 | $5,840,601 | $(1,213,578) | (20.78)% |

Consolidated selling, general and administrative expenses for the six months ended June 30, 2019 and 2018, were approximately $4.6 million and $5.8 million, respectively. The decrease of approximately $1.2 million is categorized in several areas. Bonuses decreased by $620,000 based on management decision to curtail bonuses awards for the remainder of 2019. Also the Executive Pension expense decreased by $101,000 as the Company’s funding commitment was finalized in 2018. International consulting decreased by approximately $77,000 as management decided to reduce these services in 2019. Stock based compensation decreased by $65,000 as management did not provide stock options in 2018 to the executive team. Amortization expense for patents decreased by $442,000 due to the impairment of the Apad patents in 2018. Professional fees decreased by$188,000 relating to legal and accounting projects that ended in 2018. Marketing expenses increased by $52,000 in the area of promotions and trials. Due to the quality control regulatory changes in the European community we incurred an increase in cost of approximately $116,000 for the six months ended June 30, 2019.

### Research and Development for 2019 and 2018 were as follows:

|  | 2019 | 2018 | Increase Decrease% |  |
| --- | ---: | ---: | ---: | ---: |
| Dental | $- | $- | $- | 0.00% |
| Medical | 101,875 | 65,008 | 36,867 | 56.71% |
| Corporate | - | 170,584 | (170,584) | (100.00)% |
| Total research and development | $101,875 | $235,592 | $(133,717) | (56.76)% |

Research and development expenses for the six months ended June 30, 2019 and 2018, were approximately $101,000 and $236,000, respectively. The decrease is due management discretion and curtailment in the development of several new projects that were being worked on during 2018. Management decided make modification to some Epidural instruments for the development of an Epidural trainer instruments. CompuFlo® Epidural Trainer (CompuFlo Trainer), an instructional instrument that uses pressure sensing technology to improve epidural placement success. The CompuFlo Epidural Trainer is for training purposes only and not intended for clinical use.

### Profit (Loss) from Operations for 2019 and 2018 were as follows:

|  | 2019 | 2018 | Increase Decrease% |  |
| --- | ---: | ---: | ---: | ---: |
| Dental | $1,121,440 | $1,080,249 | $41,191 | 3.81% |
| Medical | (1,156,341) | (1,554,546) | 398,205 | (25.62)% |
| Corporate | (1,891,114) | (2,952,043) | 1,060,929 | (35.94)% |
| Total loss from operations | $(1,926,015) | $(3,426,340) | $1,500,325 | (43.79)% |

The loss from operations was approximately $1.9 million and $3.4 million for six months ended June 30, 2019 and 2018 respectively. The decrease in the loss of approximately $1.5 million relates to an increase in gross profit of approximately $150,000, a reduction in administrative expenses of approximately $1.2 million and reduction in research and development expenses of approximately $135,000.The dental segment is still the primary revenue and gross profit generator for the Company. The dental segment continues to generate revenue on a steady basis in the United States and Rest of the World and manage expenses during the process. Costs in the medical segment are beginning to increase as personnel are expanded in the U.S. to focus on our domestic Epidural device business.

### Liquidity and Capital Resources

At June 30, 2019 Milestone Scientific had cash and cash equivalents of approximately $2.3 million and working capital of approximately $345,000 versus working capital of $1 million at December 31, 2018. For the six months ended June 30, 2019, we had negative cash flows from operating activities of approximately $620,000. Based on current and expected cash to be used in operating activities substantial doubt exists about the Company’s ability to continue as a going concern for at least the next twelve months from the financial reporting date.

Management believes that the current cash flow and support from the dental business will not be able to mitigate the expected selling expenditures for the Epidural medical device commercialization, as well as other operating expenditures and new product development programs, over the next twelve months from the financial reporting date. Without additional funding a delay, scale back or elimination of some or all of the Company’s medical commercial strategy or development programs could be required, all of which could have a material adverse impact on the Company.

Milestone Scientific has incurred annual operating losses and negative cash flows from operating activities since its inception. The capital raised in February 2019 (a capital raise in a public and private offering) provided Milestone Scientific with working capital to continue marketing of the CompuFlo Epidural instrument and to market its dental devices. Milestone Scientific is actively pursuing the generation of positive cash flows from operating activities through an increase in revenue from its dental business worldwide, and a reduction in operating expenses.

Now that the *CompuFlo* Epidural System has obtained FDA clearance in the United States (June 2017), the development costs were reduced in 2019 but the selling costs are expected to continue to increase. The FDA clearance has provided the Company with the opportunity to establish distribution in the USA. At the same time, the Company is looking to establish additional financing to support the Epidural device commercialization process. The intra-articular device is anticipated to restart the 510K application process later this year, if funding is available.

## Market risk

As filed, 162 characters.

Milestone Scientific is a “smaller reporting company” as defined by Regulation S-K and, as such, is not required to provide the information required by this item.

## Controls and procedures

As filed, 1,311 characters.

Milestone Scientific’s Interim Chief Executive Officer and Chief Financial Officer have evaluated the effectiveness of the design and operation of Milestone Scientific’s disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of the end of the period covered by this report. Based upon that evaluation, Milestone Scientific’s Interim Chief Executive Officer and Chief Financial Officer have concluded that the disclosure controls and procedures as of June 30, 2019 are effective to ensure that information required to be disclosed in the reports Milestone Scientific files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to Milestone Scientific's management, including the Interim Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. There have been no changes in Milestone Scientific’s internal control over financial reporting that occurred during Milestone Scientific’s last fiscal quarter that have materially affected, or that are reasonably likely to materially affect, Milestone Scientific’s internal controls over financial reporting.

Filed Aug 14, 2019.
Source: SEC EDGAR, the filing index for accession 0001437749-19-016799. Last ingested by Listed: Nov 14, 2026, 11:14 ET. No prices; not investment advice.
